Phase 2
N=52
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
Biochemical Recurrence of Malignant Neoplasm of Prostate
Bottom Line
View on ClinicalTrials.gov: NCT05249127 ↗Enrolled (actual)
52
Serious AEs
1.9%
Results posted
Oct 2024
Primary outcome: Primary: Safety and Tolerability — 10; 8; 2; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- 64Cu-SAR-bisPSMA (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Male
- Sponsor
- Clarity Pharmaceuticals Ltd
- Primary completion
- Aug 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety and Tolerability |
10; 8; 2; 0; 1; 1 | — |
| PRIMARY Participant-level Correct Detection Rate (CDR)- Day 0 |
26.2; 23.8; 19.0 | — |
| PRIMARY Participant-level CDR- Day 1 |
33.3; 33.3; 26.2 | — |
| PRIMARY Region-level Positive Predictive Value (PPV)- Day 0 |
41.2; 44.8; 39.1 | — |
| PRIMARY Region-level PPV- Day 1 |
41.5; 32.7; 43.3 | — |
| SECONDARY Biodistribution of 64Cu-SAR-bisPSMA- SUVmean |
9.898; 15.818; 8.990; 14.678; 6.635; 14.729 | — |
| SECONDARY Biodistribution of 64Cu-SAR-bisPSMA- SUVmax |
13.973; 22.198; 13.914; 22.789; 13.924; 33.363 | — |
| SECONDARY Biodistribution of 64Cu-SAR-bisPSMA- SUVr |
23.233; 118.051; 23.476; 121.306; 25.448; 181.673 | — |
| SECONDARY Participant-level PPV |
44.0; 45.2; 43.5; 40.0; 42.1; 47.8 | — |
| SECONDARY Participant-level Detection Rate (DR) |
58.0; 74.0; 56.0; 80.0; 44.0; 58.0 | — |
| SECONDARY Participant-level False Positive Rate (FPR) |
53.8; 54.8; 54.2; 60.0; 57.9; 50.0 | — |
| SECONDARY Region-level FPR |
58.8; 57.1; 55.2; 67.3; 60.9; 56.7 | — |
| SECONDARY Participant-level Discrepant PET Negativity Rate |
14.3; 21.4; 42.9 | — |
| SECONDARY Participant-level True Negative Rate (TNR) |
50.0; 39.3; 53.6; 25.0; 60.7; 57.1 | — |
| SECONDARY Region-level TNR |
88.7; 86.4; 91.0; 80.1; 92.1; 90.4 | — |
Summary
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with biochemical recurrence of prostate cancer following definitive therapy.
Eligibility Criteria
Inclusion Criteria
- At least 18 years of age.
- Signed informed consent.
- Life expectancy ≥ 12 weeks as determined by the Investigator.
- Histologically confirmed adenocarcinoma of prostate per original diagnosis and completed subsequent definitive therapy.
- Suspected recurrence of prostate cancer (PC) based on rising Prostate-specific antigen (PSA) after definitive therapy on the basis of:
- Post-radical prostatectomy: Detectable or rising PSA that is ≥ 0.2 ng/mL with a confirmatory PSA ≥ 0.2 ng/mL (per American Urological Association recommendation) or
- Post-radiation therapy, cryotherapy, or brachytherapy: Increase in PSA level that is elevated by ≥ 2 ng/mL above the nadir (per American Society for Therapeutic Radiology and Oncology-Phoenix consensus definition).
- Negative or equivocal findings for PC on conventional imaging performed as part of standard of care workup within 60 days prior to Day 0.
- The Eastern Cooperative Oncology performance status 0-2.
- Adequate recovery from acute toxic effects of any prior therapy.
- Estimated Glomerular Filtration Rate of 30 mL/min or higher.
- Adequate liver function.
- For participants who have partners of childbearing potential: Partner and/or participant must use a method of birth control with adequate barrier protection.
Exclusion Criteria
- Participants who received other investigational agents within 28 days prior to Day 0.
- Participants administered any high energy (>300 kiloelectronvolts (keV)) gamma-emitting radioisotope within 5 physical half-lives prior to Day 0.
- Ongoing treatment or treatment within 90 days of Day 0 with any systemic therapy (e.g. androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist) for PC.
- Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
- Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Data sourced from ClinicalTrials.gov (NCT05249127). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.